Detalles de la búsqueda
1.
Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111).
Int J Cancer
; 148(6): 1428-1437, 2021 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32930387
2.
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry.
Int J Cancer
; 148(6): 1478-1488, 2021 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33038277
3.
DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma.
BMC Cancer
; 16: 21, 2016 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26772812
4.
Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114).
Oncol Res Treat
; 47(6): 251-261, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38565089
5.
Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer-Results of the prospective multicenter PERMAD trial.
PLoS One
; 19(6): e0304324, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38875244
6.
Pre-study protocol MagPEP: a multicentre randomized controlled trial of magnesium sulphate in the prevention of post-ERCP pancreatitis.
BMC Gastroenterol
; 13: 11, 2013 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23320650
7.
Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study.
Cancers (Basel)
; 12(11)2020 Oct 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33121007
Resultados
1 -
7
de 7
1
Próxima >
>>